On July 28, 2016, the Patent Trial and Appeal Board (PTAB) ruled in favor of Finnegan client Bausch & Lomb, stating that generic drug makers InnoPharma Inc., Mylan Inc., and Lupin Ltd. failed to show that two Bausch & Lomb patents are invalid as obvious based on prior art.
The three generic drug makers filed a petition for inter partes review, arguing that the patents on the eye drop medication Prolensa would be obvious. However, the PTAB analyzed Bausch & Lomb's evidence and was persuaded to disagree, thus upholding every claim of the patents. The Board stated that Prolensa's unexpected results and commercial success prove that the petitioners could not demonstrate obviousness of the claimed invention.
Commentary
April 11, 2024
Media Mention
Women in Business Law Americas Awards 2024: Three Finnegan Attorneys Shortlisted
April 7, 2024
Press Release
Finnegan and BMW Group Successfully Demolish Non-Practicing Entity NorthStar’s Efforts
April 3, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.